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Summary Neoplastic events are marked by uncontrolled cell proliferation. One major focus of cancer research has been to identify
treatments that reduce or inhibit cell growth. Over the years, various compounds, both naturally occurring and chemically synthesized, have
been used to inhibit neoplastic cell proliferation. Two such oncostatic agents, melatonin and retinoic acid, have been shown to suppress the
growth of hormone-responsive breast cancer. Currently, separate clinical protocols exist for the administration of retinoids and melatonin as
adjuvant therapies for cancer. Using the oestrogen receptor (ER)-positive MCF-7 human breast tumour cell line, our laboratory has studied
the effects of a sequential treatment regimen of melatonin followed by all-trans retinoic acid (atRA) on breast tumour cell proliferation in vitro.
Incubation of hormonally responsive MCF-7 and T47D cells with melatonin (10-9 M) followed 24 h later by atRA (10-9 M) resulted in the
complete cessation of cell growth as well as a reduction in the number of cells to below the initial plating density. This cytocidal effect is in
contrast to the growth-suppressive effects seen with either hormone alone. This regimen of melatonin followed by atRA induced cytocidal
effects on MCF-7 cells by activating pathways leading to apoptosis (programmed cell death) as evidenced by decreased ER and Bcl-2 and
increased Bax and transforming growth factor beta 1 (TGF-f1) expression. Apoptosis was reflected morphologically by an increase in the
number of lysosomal bodies and perinuclear chromatin condensation, cytoplasmic blebbing and the presence of apoptotic bodies. The
apoptotic effect of this sequential treatment with melatonin and atRA appears to be both cell and regimen specific as (a) ER-negative MDA-
MB-231 and BT-20 breast tumour cells were unaffected, and (b) the simultaneous administration of melatonin and atRA was not associated
with apoptosis in any of the breast cancer cell lines studied. Taken together, the results suggest that use of an appropriate regimen of
melatonin and atRA should be considered for preclinical and clinical evaluation against ER-positive human breast cancer.
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Melatonin, the major hormonal product of the pineal gland, has
repeatedly been shown to exert a negative growth-regulatory influ-
ence on the development and growth ofhormone-responsive breast
cancer (Blask et al, 1986, 1991). In addition, our laboratory (Hill
and Blask, 1988) as well as others (Cos and Sanchez-Barcel6, 1994)
have shown that melatonin treatment can act directly on hormone-
responsive human breast cancer cells in vitro to suppress their
proliferation. We have also recently reported that melatonin not only
suppresses the expression of the oestrogen receptor (ER) gene
(Molis et al, 1994), but also up-regulates steady-state mRNA levels
of transforming growth factor beta (TGF-f) and the proto-onco-
gene, c-mync (Molis et al, 1995). Even though the effects of mela-
tonin on various growth-modulatory pathways have been observed,
the exact mechanism by which melatonin suppresses breast tumour
cell growth has not been conclusively identified. Two basic mecha-
nisms have been proposed through which melatonin inhibits breast
tumour cell growth. One mechanism is through a direct effect on
breast tumour cells and the other through an indirect, neuroendo-
crine effect mediated via the hypothalamic-pituitary axis. Recent
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reports suggest that two basic types ofmelatonin receptor exist. The
first type consists of two related, yet distinct, isoforms (Mella and
Mellb) ofcell membrane proteins (Ebisawa et al, 1994; Reppert et al,
1995). The second putative melatonin receptorconsists ofa group of
nuclear receptors ofthe steroid hormone receptor superfamily that is
closely associated with retinoic acid receptors. These putative mela-
tonin receptors include the RZRa and RZRf (RORa) receptors
(Becker-Andre et al, 1994; Steinhilber et al, 1995).
Studies using human breast cancer cell lines indicate that
retinoids inhibit the growth ofER-positive but not ER-negative cell
lines (Lotan, 1979; Lacroix and Lippman, 1980; van der Burg et al,
1993), with the exception of the ER-negative MDA-MB-157 cell
line. Several growth-regulatory pathways are affected when breast
tumour cell lines are exposed to retinoic acid (RA) (Lotan, 1979;
Lacroix and Lippman, 1980; van der Burg et al, 1993). For
example, RA increases the activity of insulin-like growth factor
binding protein one (IGF-BP-1), thereby reducing the mitogenic
efficacy ofIGF-1 in MCF-7 cells (Fontana et al, 1991). In addition,
treatment of ER-positive MCF-7 and T47D human breast cancer
cells with RA induces secretion of growth-related proteins,
including TGF-f (Fontana et al, 1990) and suppresses the expres-
sion of several key growth-regulatory proteins, including ER, pro-
gesterone receptor (PgR) and TGF-ox (Clarke et al, 1990; Rubin et
al, 1994). Differentiation and loss ofher-2/neu expression may also
be induced by RA (Bacus et al, 1990). The effects of the retinoids,
all-trans-RA (atRA) and 9-cis-RA (9cRA), are mediated by a
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Figure 1 Effects of melatonin and atRA on the proliferation of MCF-7, T47D
and MDA-MB-231 cells. MCF-7 (A) and MDA-MB-231 (C) cells were seeded
at a density of 2 x 106 cells ml-1 and T47D (B) at 5 x 105 cells ml-' in Costar
six-well dishes in IDMEM supplemented with 10% CS-FBS. Five hours after
seeding (day 0), melatonin or atRA, both melatonin and atRA, atRA followed
24 h later by melatonin or melatonin followed 24 h later by atRA were added
as 1000-fold concentrates to the appropriate wells. Ethanol vehicle was
added to the control plates such that the final concentration was 0.001%. On
days 1, 3 and 5, cells were harvested by brief trypsinization, and viable cells
were enumerated based on trypan blue exclusion using a haemacytometer.
Each point represents the mean cell count + s.e.m. from six plates containing
either the vehicle (Veh), 10-9 M melatonin (Mel), 10-9 M atRA (RA), melatonin
plus atRA (M + R) or melatonin followed 24 h later by atRA (M24 + R) 0,
*P < 0.05, **P < 0.01 vs vehicle-treated controls
family of nuclear retinoid receptors. This family consists of the
retinoic acid receptors (RARoc, RAR3, RARy), which mediate the
effects ofatRA, and the related RXRs, which also have oc, P and y
counterparts, that mediate the effects of9cRA (Giguere et al, 1987;
Petkovich et al, 1987; Benbrook et al, 1988; Krust et al, 1989).
Hormonal treatment of breast cancer is frequently associated
with cytostatic rather than cytocidal effects, and tumours often
evolve under selective pressure to become resistant to endocrine
therapy in breast cancer management (Miller, 1990). The combi-
natory use ofdrugs with anti-oestrogenic effects might, thus, be an
alternative to classical endocrine therapy. In this paper, we demon-
strate that a sequential regimen of melatonin for 24 h followed by
atRA results in decreased expression of ER and a significant
induction of TGF-,B expression, and that the combined effect of
melatonin and atRA induces apoptosis in hormone-responsive
breast tumour cells.
MATERIALS AND METHODS
Materials
Materials for cell culture and random priming kits were purchased
from Gibco-BRL (Gaithersburg, MD, USA). 17-P Oestradiol,
atRA and melatonin were purchased from Sigma (St Louis, MO,
USA), and effector solutions were prepared in ethanol. RNAzol B
reagent was purchased from Cinna-Biotex Laboratories (Houston,
TX, USA), Hybond nylon transfer membrane was purchased
from Amersham (Arlington Heights, IL, USA) and nitrocellulose
membranes were purchased from Schleicher and Schuell (Keene,
NH, USA). XOMAT-AR film was purchased from Eastman Kodak
(Rochester, NY, USA). The MCF-7 and T47D cells were provided
by the laboratory of the late William L McGuire (San Antonio,
TX, USA), the MDA-MB-231 cells were obtained from the labo-
ratory of CK Osborn (San Antonio) and the BT-20 cells were
purchased from the American Type Tissue Culture Collection
(Rockville, MD, USA).
Cell line and culture conditions
All breast tumour cell lines, MCF-7, T47D, MDA-MB-231 and
BT-20 were cultured in improved Dulbecco's modified Eagle
medium (IDMEM) supplemented with 10% fetal bovine serum
(FBS), 50 mm non-essential amino acids, 2 mM L-glutamine,
100 U ml penicillin, 100 gg ml streptomycin and 10-8 M
porcine insulin. Experiments with melatonin and atRA were
performed under subdued light.
Cell proliferation studies
MCF-7 and MDA-MB-231 cells were plated at a density of2 x 106
cells ml-' and BT-20 and T47D cells were plated at a density of
5 x 10- cells ml-' in 60-cm2 wells of six-well plates in IDMEM
supplemented with 10% FBS. Five hours after seeding, the cells
were treated with melatonin (10-9M), atRA (109M) or a combina-
tion ofthe two hormones. For timed regimens, the cells were treated
with either melatonin or atRA for 24 h before the addition of the
other hormone. The cells were grown, protected from light, in a
humidified atmosphere in 5% CO2 at 37°C. On specific days (1,3 or
5), triplicate wells were trypsinized, mixed with 2% trypan blue, and
both total and viable cells were counted on a haemacytometer.
DNA extraction and electrophoresis
Total cellular DNA was isolated as previously described (Nicoletti
et al, 1991). Cells (1.5 x 107) were washed and resuspended in
0.5 ml of lysis buffer (50 mM Tris, 10 mM EDTA, 0.5% Triton X-
100) with 5 mg ml' proteinase K and incubated at 37°C for 12 h.
Lysates were then brought to a volume of 2.5 ml with lysis buffer
and extracted twice with phenol-chloroform. DNA was precipi-
tated, resuspended in 10 mM Tris (pH 8.0) with 0.1 mM EDTA and
digested with 0.2 mg RNAase A for 2 h at 37°C. Approximately
20,tg of DNA from each sample was size fractionated on a 2%
agarose gel, stained with ethidium bromide and photographed by
UV transillumination to assess DNA oligomerization.
Transmission electron microscopy
MCF-7 cells were cultured in IDMEM supplemented with 10%
FBS and plated at a density of 1 x 107 cells in a 75-cm2 flask. Cells
were treated either with diluent (ethanol) or with melatonin
(10-9 M) followed 24 h later by atRA (10-9 M). After 12, 24, 48 or
72 h of treatment, cells were harvested with a Ca2+-, Mg2+-free
PBS/EDTA solution and pelleted by centrifugation (1000 g) for
5 min. Cell pellets were fixed in glutaraldehyde (3%) for 1.5 h and
post-fixed with osmium tetroxide (2%) for 1 h in phosphate buffer
(pH 7.3). The cells were then embedded in Epox. Ultra-thin
(70 nm) sections were cut with a diamond knife, stained with 5%
uranyl acetate and lead citrate, and were viewed with the JEOL
CX II electron microscope at 60 kV.
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Figure 2 Electrophoretic analysis of DNA isolated from MCF-7 cells grown
in IDMEM supplemented with 10% FBS was performed after treatment with
the timed regimen of melatonin and atRA. The molecular weight marker in
this figure is a combination of x DNA digested with Hindolll and 4) 174
digested with Haelll. MCF-7 cells were treated for 1, 3 or 5 days with the
sequential regimen of melatonin and atRA (M + R), after which high
molecular weight DNA was isolated as described in Materials and methods.
DNA (20 igg) was run on a 2.0% agarose gel. This is a representative picture
of three separate experiments
Northern blot analysis of ER and TGF-p1 mRNA
MCF-7 cells were seeded at a density of 3.0 x 106 cells per 150-
cm2 flask in phenol red-free IDMEM supplemented with 5% CS-
FBS. After 5 days in oestrogen-deficient medium, the cells were
treated with either ethanol, melatonin (10-9 M), atRA (10-9 M) or a
timed regimen ofmelatonin followed 24 h laterby atRA. All treat-
ments were continued for 24, 48 or 72 h. At the end of the treat-
ment period, total RNA was isolated according to the method of
Chomczynski and Sacchi (1987) using the RNAzol B reagent.
Total RNA (50jg) was separated electrophoretically on a 1%
denaturing agarose gel containing 2.2 M formaldehyde and trans-
ferred to Hybond membranes by capillary action. The membranes
were hybridized overnight with 32P-labelled ER, TGF-P, or 36B4
cDNA probes at 42°C. After high-stringency washes, filters were
exposed to Kodak XOMAT-AR film with intensifying screens.
Autoradiographs were scanned on the BioRad Imaging
A
Figure 3 Transmission electron micrographs of MCF-7 cells following treatment with the sequential regimen of melatonin followed by atRA. Micrographs are
representative of (A) control untreated cells, or cells subjected to the sequential treatment of melatonin followed by atRA at 12 h (B), 24 h (C), 48 h (D) and 72 h
(E). The following characteristics associated with apoptosis were observed: (a) increased lysosomal bodies, (b) increased perinuclear chromatin condensation,
(c) membrane and cytoplasmic blebbing, and (d) formation of membrane-bound apoptotic bodies
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Densitometer GS-670 to determine the amount of ER and TGF-, 1
relative to 36B4 mRNA. Results were expressed as percentages of
ER and TGF-4 1 mRNA levels in response to melatonin, atRA or
the sequential regimen of melatonin and atRA compared with
diluent controls.
Western blot analysis of Bcl-2 and Bax expression
MCF-7 cells were treated with either diluent, melatonin, atRA or
the sequential treatment of melatonin and atRA. Cultured cells
were then washed twice with PBS and lysed in 300 p1 10-7 cells in
50 mM Tris (pH 8.0), 150 mm NaCl, 0.1% sodium dodecyl sulphate
(SDS), 0.5% sodium deoxycholate, 0.1% Triton X, 10 g ml'
phenlymethylsulphonyl fluoride, 1 tg ml' aprotinin, I ,ug ml-'
leupeptin and 0.02% sodium azide for 30 min at 4°C. Insoluble
material was removed by centrifugation at 12 000g for 15 min, and
protein concentrations were determined using the BCA protein
assay kit. The proteins (25 ,ug per lane) were size fractionated
under denaturing conditions on 12.5% SDS-polyacrylamide gels
and transferred to nitrocellulose membranes. Western blot analysis
for Bcl-2 and Bax was conducted using rabbit polyclonal anti-
bodies specific for the human Bcl-2 and Bax proteins as previously
described (Krajewski et al, 1995) and an actin rabbit polyclonal
antibody (Sigma) as a loading control. The proteins were visualized
after incubation with horseradish peroxidase-conjugated secondary
antibody (Sigma) and chemiluminescent substrate (Amersham),
and exposure to Kodak XOMAT-AR film. Autoradiographs were
scanned densitometrically to determine the amount of Bcl-2 and
Bax proteins relative to the actin protein. Results were normalized
to actin protein levels and are expressed as per cent of each day's
individual control.
RESULTS
A sequential regimen of melatonin followed by atRA is
cytocidal in ER-positive MCF-7 and T47D but not in
ER-negative MDA-MB-231 or BT-20 human breast
cancer cells
In light of recent reports that melatonin may be a ligand for the
RORox receptors, that both melatonin and atRA can suppress the
growth of ER-positive breast cancer cells (Lacroix and Lippman,
1980; Hill and Blask, 1988) and that the RORc and RARx recep-
tors may crosstalk at the level of hormone response element, we
initiated a series of studies to examine the possible additive or
synergistic effects of melatonin and retinoic acid. As shown in
Figure 1A, ER-positive MCF-7 breast tumour cells showed signifi-
cant growth suppression to 64% and 62% ofcontrol after 5 days of
either melatonin (10-9 M) or atRA (10-9 M) treatment respectively.
Surprisingly, the simultaneous treatment of cells with melatonin
and atRA had no inhibitory effect on cell proliferation, and these
cell numbers were equivalent to control values. However, a sequen-
tial regimen of melatonin (I0 9M) followed 24 h later by atRA
(10-9 M) resulted in a cytocidal effect, decreasing cell numbers to
below the initial plating density after 5 days of treatment.
Sequential treatment with retinoic acid followed 24 h laterby mela-
tonin had a cytostatic effect in which cell proliferation was inhib-
ited to 48% of control, but not a cytocidal effect. Similar results
were seen with the ER-positive T47D cell line (Figure 1B) in which
melatonin and atRA, when used alone, inhibited cell proliferation
to 60% and 61 % ofcontrol respectively; however, the simultaneous
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Figure 4 Effects of treatment with melatonin or atRA alone vs the
sequential regimen of melatonin and atRA on steady-state ER and TGF-,1l
mRNA levels in MCF-7 cells cultured in medium supplemented with 5% CS-
FBS. MCF-7 cells were incubated with ethanol diluent (control), 10-9 M
melatonin (Mel), 10-9 M atRA (atRA) or a regimen of melatonin followed 24 h
later by atRA (M + R). For each time point, 50 ig of total RNA was
fractionated on denaturing 1% agarose gels and blotted as described in
Materials and methods. Northern blots were probed with 32P-labeled human
ER and human TGF-,B1 cDNAs. The 36B4 cDNA was used to monitor RNA
loading. A representative autoradiograph is shown in (A). Autoradiographs
from Northern blot analyses were quantified by scanning densitometry and
normalized to 36B4 mRNA. Results are presented graphically in (B) as
per cent of control (n = 3 independent experiments). *P < 0.001 vs controls,
**P < 0.005 vs melatonin oratRA alone
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administration of melatonin and atRA also inhibited cell growth
(54% vs control). T47D cells, like MCF-7 cells, showed acytocidal
response to the sequential regimen of melatonin and atRA.
Sequential treatment with retinoic acid followed 24 h later by mela-
tonin caused a cytostatic effect in which cell proliferation was
inhibited to 39% ofcontrol, but a cytocidal effect was not observed.
The specificity of the cytocidal effects is demonstrated by the fact
that the sequential melatonin and atRA regimen had no effect on
ER-negative MDA-MB-23 1 breast cancer cells (Figure 1C) nor on
ER-negative BT-20 cells (data not shown).
Electrophoretic analysis of DNA isolated from MCF-7
cells treated at various times with the sequential
regimen of melatonin and atRA
The pattern of DNA oligomerization in MCF-7 tumour cells was
determined at various times following the initiation of the sequen-
tial regimen of melatonin followed by atRA (Figure 2). Following
treatment, the development, over time, of a ladder of nucleosomal
oligomers was evident in MCF-7 cells. This laddering is character-
istic of many cell types undergoing apoptosis. It should also be
noted that there was no evidence of complete DNA degradation,
which would be expected if the cells were undergoing cellular
necrosis in response to treatment with melatonin followed byatRA.
Morphological changes in MCF-7 cells treated with the
sequential regimen of melatonin and atRA
Apoptosis is delineated from cellular necrosis by a unique series of
ultrastructural changes, including chromosomal and cytoplasmic
condensation, nuclear fragmentation, membrane blebbing,
increased number of lysosomal bodies and the formation of
membrane-bound apoptotic bodies. Following treatment with the
sequential regimen of melatonin and atRA, MCF-7 cells were
examined for ultrastructural changes indicative of necrosis or
apoptosis. No distinctive morphological changes were noted in
cells treated with the sequential regimen of melatonin and atRA
until after 24 h of treatment, at which time an increase in lyso-
somal bodies, and perinuclear chromatin condensation was
observed as compared with controls (Figure 3A-C). By 48 h, there
was a further increase in the presence of lysosomal bodies and
perinuclear chromatin condensation, and the cells had begun to
demonstrate membrane blebbing (Figure 3D). After 72 h of treat-
ment, membrane and cytoplasmic blebbing had increased and
membrane-bound apoptotic bodies were evident. Based on the
morphological criteria, it is evident that the treatment of MCF-7
cells with melatonin followed by atRA induced apoptosis rather
than necrosis.
Effects of melatonin and atRA on the expression of the
steady-state levels of ER and TGF-P mRNAs
The expression of the steady-state levels of mRNAs encoding the
ER and TGF-31 was examined by Northern blot analysis in MCF-
7 cells following 48 h of treatment with melatonin or atRA alone
or with the sequential regimen of melatonin and atRA. For these
studies, MCF-7 cells were grown for 5 days in oestrogen-deficient
medium and treated with either melatonin or atRA alone (10-9 M)
or pretreated with melatonin for 24 h before the addition of atRA.
Figure 4A shows that both atRA and melatonin alone significantly
decreased the steady-state level of ER mRNA by 62% and 79%
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Figure 5 The temporal effects of the sequential regimen of melatonin and
atRA on steady-state TGF-,1 mRNA expression in MCF-7 cells. MCF-7 cells
were cultured in medium supplemented with 5% CS-FBS. MCF-7 cells were
incubated with diluent (ethanol), or a regimen of melatonin followed 24 h later
by atRA for 1, 2 or 3 days. For each time point, 50 pg of total RNA was
fractionated on denaturing 1% agarose gels and blotted as described in
Materials and methods. Northern blots were probed with 32P-labeled human
TGF-,B1 cDNAs. The 36B4 cDNA was used to monitor RNA loading. A
representative autoradiograph is shown in (A). Autoradiographs from
Northern blot analyses were quantified by scanning densitometry and
normalized to 36B4 mRNA (n = 3 independent experiments). Results are
presented graphically as per cent of control (B). *P < 0.001 vs controls,
**P < 0.05 vs day 1 or 2 of treatment
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respectively (P < 0.01 vs control). However, the sequential
regimen of melatonin and atRA reduced ER mRNA expression to
almost undetectable levels (P < 0.001 vs melatonin or atRA
alone). In addition, both atRA and melatonin alone enhanced the
steady-state level of TGF-31 mRNA by 40% and 53% respec-
tively, whereas the sequential regimen produced a super-induction
ofTGF- I mRNA levels (91% increase overcontrol, and 65% and
52% increase over atRA or melatonin treatment respectively).
Figure SA shows a representative Northern blot analysis of the
time course of TGF-1 mRNA expression in response to the
sequential treatment of MCF-7 cells with melatonin followed by
atRA. By days I and 2 of treatment, TGF- 1 mRNA levels were
increased 30% and 70%, respectively, over controls (Figure SB).
By day 3,TGF-p1 mRNA was markedly elevated to approximately
200% over diluent controls. These results suggest that the sequen-
tial treatment of MCF-7 cells with melatonin followed by atRA
results in a synergistic induction ofTGF-f1 mRNA expression.
Temporal expression of Bcl-2 and Bax in MCF-7 cells in
response to the timed treatment of melatonin and atRA
The relative levels of the Bcl-2 and Bax proteins were examined
by Western blot analysis. Figure 6A and B shows representative
Western blots of Bcl-2 and Bax expression 5 days after pretreat-
ment with melatonin followed 24 h later by atRA. Densitometric
analysis ofthese and otherWestern blots is shown in Figure 7. The
levels of Bcl-2 exhibited the greatest divergence from control
levels on days 3 and 4, at which time Bcl-2 expression was
reduced by 64% and 66% respectively as compared with control.
Conversely, Bax expression appeared to decrease as compared
with controls on day 4; however, this decrease was not statistically
significant. On day 5, however, Bax expression was significantly
increased over control by 58%. These results suggest that the
sequential treatment regimen of melatonin followed by atRA
suppresses the expression ofthe 'death suppresser', Bcl-2, on days
2, 3, 4 and 5 and enhances the expression of the 'death inducer',
Bax, only on day 5.
DISCUSSION
Previous work by our laboratory (Hill and Blask, 1988), as well as
that of others (Cos and Sainchez-Barcelo, 1994), has clearly
demonstrated the growth-inhibitory effect of melatonin on human
breast tumour cells. In addition, numerous laboratories have
reported that both atRA and 9cRA are effective inhibitors ofbreast
tumour cell proliferation (Lotan, 1979; Lacroix and Lippman,
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Figure 6 The temporal effects of the sequential regimen of melatonin and atRA on Bcl-2 and Bax protein expression in MCF-7 cells. MCF-7 cells were
incubated with diluent (control) or a regimen of melatonin followed 24 h later by atRA (M + atRA) for 1, 2, 3, 4 or 5 days. For each time point, 25 ,ug of total
cellular protein per lane was fractionated on 12.5% polyacrylamide gels and transferred to nitrocellulose membranes as described in Materials and methods.
Western blots were probed with polyclonal antibodies specific for Bcl-2 and Bax, and proteins were visualized after incubation with a horseradish peroxidase-
conjugated secondary antibody and chemiluminescent substrate. Actin protein levels were used to monitor protein loading. Representative Western blots for
Bcl-2 (A) and Bax (B) during 5 days of treatment with melatonin followed 24 h later by atRA are shown
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Figure 7 Time-course changes in Bcl-2 and Bax protein levels after
sequential treatment of MCF-7 cells with melatonin followed by atRA.
Autoradiographs from Western blot analyses of the time course of Bax (solid
bars) and Bcl-2 (open bars) proteins in response to the sequential treatment
of melatonin and atRA were quantified by scanning densitometry and
normalized to actin protein levels. Results are presented graphically as per
cent of control (n = 3 independent experiments). *P < 0.05 vs controls
1980; Fontanaet al. 1990, 1991; van der Burg et al, 1993; Rubin et
al, 1994). Although each hormone has been shown to slow tumour
proliferation, neither hormone alone has been shown to produce
cytocidal effects in breast cancer cells at physiological concentra-
tions. However, the results presented here show that, when used in
a sequential manner (melatonin followed 24 h later by atRA),
these hormones are able to act in an additive or synergistic manner
to induce a cytocidal response and apoptosis in hormone-respon-
sive breast tumour cells. For example, the formation of nucleo-
somal DNA oligomers, a phenomenon seen in many cells
undergoing programmed cell death, was evident after treatment of
MCF-7 cells with the timed regimen of melatonin and atRA.
Furthermore, based on the morphological criteria of chromosomal
condensation, nuclear fragmentation, membrane blebbing,
increased number of lysosomal bodies and the formation of
membrane-bound apoptotic bodies, it was clear that MCF-7 cells
were undergoing apoptosis rather than necrosis in response to this
treatment paradigm. The cytocidal effects produced by the sequen-
tial regimen of melatonin and atRA do not appear to result from
non-specific cytotoxic effects, but, rather, are probably cell and
treatment specific. This is evident by the lack of response of ER-
negative (hormone-insensitive) MDA-MB-231 and BT-20 cells to
the sequential regimen, and by the failure of the simultaneous
administration of melatonin and atRA to induce apoptosis.
However, as we did not specifically quantify the number of cells
undergoing apoptosis vs those undergoing a more general cyto-
cidal response, we cannot definitively say that apoptosis was the
primary contributor to this cytocidal effect.
An interesting observation was that simultaneous treatment of
MCF-7 cells with melatonin and atRA did not suppress cell prolif-
eration, but rather cell numbers were equivalent to control values.
This may be due to a time-dependent response in which melatonin
may potentiate the effects of retinoic acid, possibly through either
up-regulation or phosphorylation of the retinoic acid receptor or
through modulation of the ER. Studies are currently under way in
our laboratory to investigate these possibilities. The observation
that simultaneous treatment of MCF-7 cells with melatonin and
atRA failed to suppress cell proliferation is in contrast to the effect
seen in T47D cells, in which the simultaneous use of melatonin
and atRA did inhibit cell proliferation, but not to any greater
degree than either hormone alone. The results also show that,
whereas a sequential treatment regimen of retinoic acid followed
24 h later by melatonin results in a cytostatic effect on cell prolif-
eration, a cytocidal response is seen only with the sequential treat-
ment of melatonin followed 24 h later by retinoic acid. Studies are
currently being conducted to better characterize this sequence-
dependent effect, as well as the antagonistic response that occurs
when melatonin and retinoic acid are administered simultaneously.
These observations suggest that there is some level of crosstalk
between the melatonin and RA signalling pathways and that the
signalling pathways between the MCF-7 and T47D cell lines may
be somewhat different. Most evidence suggests that the effects of
melatonin are mediated via membrane-associated receptors, two of
which (Mel1 and MelIb) have recently been cloned (Ebisawa et al,
1994; Reppert et al, 1995). Although controversial, some reports
have also suggested that melatonin is able to bind and activate
nuclear RORox receptors (Becker-Andre et al, 1994; Steinhilber
et al, 1995). Transcripts for both of these receptors (MelIa and
RORoc) are expressed in MCF-7 cells (manuscript in preparation).
This is an interesting observation as we have found that transcripts
for the RORoc2, 3 and 4 mRNAs, but not RORPxl, are expressed in
MCF-7 but not in MDA-MB-231 cells (Ram and Hill, 1995). If
melatonin's effects are mediated via the membrane receptors, it is
possible that cross-talk could occur between the melatonin and RA
signalling pathways via phosphorylation of RAR or RXR recep-
tors. However, crosstalk between the RORox and RAR/RXR recep-
tors has already been demonstrated at the level of the hormone
response element (Tini et al, 1995).
Expression of the 'death suppresser', Bcl-2 has previously been
shown to be up-regulated by oestrogens in MCF-7 cells (Teixeira
et al, 1995), a process clearly mediated via the ER. The significant
diminution of ER mRNA levels in response to the sequential
regimen of melatonin and atRA raises the possibility that the
down-regulation of Bcl-2 expression by this treatment is mediated
indirectly via the reduction in ER expression. However, the lack of
a 1:1 correlation between the per cent reduction in the levels of ER
and Bcl-2 suggests that this treatment regimen may involve addi-
tional pathways that modulate Bcl-2 expression. Another potential
contributor to these apoptotic effects could be the up-regulation of
Bax protein seen on day 5 of the sequential treatment with mela-
tonin and atRA. However, as Bax expression on day 4 appeared to
decrease (not significantly) compared with controls, and as the
increase in Bax expression observed on day 5 appeared much later
than the onset of apoptosis in these cells, it is probable that this is a
secondary effect rather than a primary contributor to the onset of
apoptosis and must be interpreted with caution. It may be that the
overall ratio of the 'death suppresser' (Bcl-2) to the 'death
inducer' (Bax) is more important in mediating the apoptotic effects
than is either one alone.
It is also possible that Bcl-2- and Bax-associated pathways play
a secondary role, and that the overexpression of TGF-f1 induced
by this sequential melatonin and atRA treatment is the critical
event leading to apoptosis. TGF-f 1 has been shown to be a potent
growth inhibitor of breast epithelium and breast tumour cells,
particularly MICF-7 cells (Arteaga et al, 1990). It is also known
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that oestrogen down-regulates TGF-131 expression and secretion in
MCF-7 cells, and that the antioestrogen tamoxifen can block
oestrogen's suppressive effect and promote enhanced TGF-I1
synthesis and secretion (Knabbe et al, 1987). We have previously
demonstrated that melatonin can up-regulate TGF- 1 mRNA
expression in a time course independent ofthe effects ofoestrogen
(Molis et al, 1995). Thus, for the sequential treatment in which
super-induction of TGF- 1 expression occurs, two mechanisms
are possible. First, the effects of this regimen may be mediated
solely through the down-regulation of the oestrogen-response
pathway and the secondary up-regulation of TGF-I1 levels.
Alternatively, the effects on TGF-5l may be mediated by multiple
pathways, including the oestrogen-response pathway. Studies are
currently under way to determine if this sequential regimen of
melatonin and atRA can induce apoptosis in the face of experi-
mentally achieved reductions in TGF-j l levels.
Both melatonin and RA can inhibit the proliferation of various
malignant cell types, including breast cancer. However, only
retinoids have been shown to induce cell death and often when
employed at supraphysiological concentrations (Lacroix and
Lippman, 1980). Thus, at least for RA, the major drawback to its
use as a therapeutic agent is the toxicity induced at pharmacolog-
ical doses. For this reason, the development ofcombinatorial ther-
apies which would reduce the concentrations needed for clinical
efficacy yet still enhance anti-tumorigenic activity would be of
great benefit. Our data indicate that the antiproliferative effects of
melatonin and RA on human breast cancer cells may be additive or
synergistic when administered in the appropriate order, time and
dose. In fact, when used in a given paradigm, they may be able to
induce specifically apoptosis ofbreast tumour cells and the regres-
sion of breast tumours. This treatment regimen has been tested
only in cultured breast cancer cells; therefore, the effects on
primary human breast tumours or cell lines grown as xenografts
may be very different from the effects observed in our long estab-
lished MCF-7 breast cancer cell line. Our laboratory currently has
studies in progress to investigate further the potential effects of
our sequential treatment regimen on N-nitroso-Nmethylurea
(NMU)-induced mammary tumours in the rat animal model. In
order to define the optimal treatment parameters to induce tumour
regression in vivo, a more detailed understanding ofthe biochem-
ical pathway(s) involved in programmed cell death of breast
tumour cells is needed.
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